{
    "clinical_study": {
        "@rank": "45128", 
        "arm_group": [
            {
                "arm_group_label": "Mifepristone 2.5 mg daily for three months", 
                "arm_group_type": "Experimental", 
                "description": "Experimental: 1"
            }, 
            {
                "arm_group_label": "Mifepristone 5 mg daily for three months", 
                "arm_group_type": "Experimental", 
                "description": "Experimental: 2"
            }
        ], 
        "brief_summary": {
            "textblock": "Objectives: to evaluate the efficacy, safety and quality of life by using 2.5 and\n      mifepristone 5 mg daily doses to treat uterine fibroids over 3 months with a 9 months\n      follow-up period.\n\n      The hypothesis of the study is that the 2.5 mg dosage resulted in a lesser reduction in\n      fibroid size but a similar improvement in quality of life when compared to the 5 mg dose."
        }, 
        "brief_title": "Mifepristone to Treat Uterine Fibroids", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Uterine Fibroids", 
        "condition_browse": {
            "mesh_term": [
                "Leiomyoma", 
                "Myofibroma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Women, in fertile age or in premenopausal status, presenting symptomatic uterine fibroids\n      were randomly assigned to receive 5 mg or 10 of mifepristone.\n\n      The diminishing of prevalence of symptoms attributable to uterine fibroids is the most\n      important goal to achieve under both treatments. The possible side effects of mifepristone\n      are slight and women's adherence to treatment is remarkable. Also the reduction of the\n      volumes of the uterus and fibroids contribute to enhance the wellbeing of subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic uterine leiomyomata\n\n          -  Reproductive age or premenopausal\n\n          -  Accepting the use of non hormonal contraception\n\n          -  Conformity in keeping a monthly log of all episodes of vaginal bleeding during the\n             treatment as well as all side effects of mifepristone\n\n          -  Agreeing to have ultrasound examinations in every follow-up or evaluation visit\n\n          -  Agreeing to two endometrial biopsies: one before starting treatment and another in\n             the following 10 days after treatment termination\n\n        Exclusion Criteria:\n\n          -  Pregnancy or desire to become pregnant\n\n          -  Breastfeeding\n\n          -  Hormonal contraception or any hormonal therapy received in the last three months\n\n          -  Signs or symptoms of pelvic inflammatory disease\n\n          -  Adnexal masses\n\n          -  Abnormal or unexplained vaginal bleeding\n\n          -  Suspected or diagnosed malignant neoplastic disease\n\n          -  Signs or symptoms of mental illness\n\n          -  Adrenal disease\n\n          -  Sickle cell anemia\n\n          -  Hepatic disease\n\n          -  Renal disease\n\n          -  Coagulopathy\n\n          -  Any other severe or important disease\n\n          -  Any contraindication to receiving antiprogestins"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01786226", 
            "org_study_id": "Fibroma2.5normal"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mifepristone 2.5 mg daily for three months", 
                "description": "Experimental: 1", 
                "intervention_name": "Oral administration of mifepristone 2.5 mg daily for three months", 
                "intervention_type": "Drug", 
                "other_name": "Low doses of antiprogestins to treat uterine fibroids"
            }, 
            {
                "arm_group_label": "Mifepristone 5 mg daily for three months", 
                "description": "Experimental: 2", 
                "intervention_name": "Oral administration of mifepristone 5 mg daily for three months", 
                "intervention_type": "Drug", 
                "other_name": "Low doses of antiprogestins to treat uterine fibroids"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mifepristone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "leiomyoma, fibroid, mifepristone, antiprogestins", 
        "lastchanged_date": "February 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ciudad Habana", 
                    "country": "Cuba", 
                    "state": "Havana", 
                    "zip": "11400"
                }, 
                "name": "Hospital Eusebio Hern\u00e1ndez"
            }
        }, 
        "location_countries": {
            "country": "Cuba"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Uterine Myoma With 2.5 or 5 mg Mifepristone Daily During 3 Months With 9 Months Post-treatment Follow-up. Randomized Clinical Trial.", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Cuba: Scientific and Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluate efficacy were the percentage changes in fibroid volumes  before starting, 3 into treatment and 3, 6, and 9 months after its termination", 
            "measure": "Volume of the uterine leiomyomata with 2,5mg vs 5 mg daily of mifepristone after 3 months of treatment", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01786226"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mediterranea Medica S. L.", 
            "investigator_full_name": "Dr. Josep LLuis Carbonell i Esteve", 
            "investigator_title": "Medical Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Evaluate efficacy were the percentage changes in uterus volumes  before starting, 3 into treatment and 3, 6, and 9 months after its termination", 
            "measure": "Volume of the uterus with 2,5 mg vs 5 md daily of mifepristone after 3 months of treatment.", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "source": "Mediterranea Medica S. L.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mediterranea Medica S. L.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}